Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Cash & Equivalents (2017 - 2025)

Crinetics Pharmaceuticals has reported Cash & Equivalents over the past 9 years, most recently at $101.5 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $101.5 million for Q4 2025, down 61.62% from a year ago — trailing twelve months through Dec 2025 was $101.5 million (down 61.62% YoY), and the annual figure for FY2025 was $101.5 million, down 61.62%.
  • Cash & Equivalents for Q4 2025 was $101.5 million at Crinetics Pharmaceuticals, down from $110.9 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CRNX hit a ceiling of $1.3 billion in Q1 2025 and a floor of $30.9 million in Q3 2022.
  • Median Cash & Equivalents over the past 5 years was $126.8 million (2023), compared with a mean of $202.2 million.
  • Biggest five-year swings in Cash & Equivalents: crashed 83.11% in 2022 and later surged 861.14% in 2024.
  • Crinetics Pharmaceuticals' Cash & Equivalents stood at $201.2 million in 2021, then crashed by 83.11% to $34.0 million in 2022, then soared by 61.59% to $54.9 million in 2023, then skyrocketed by 381.89% to $264.5 million in 2024, then crashed by 61.62% to $101.5 million in 2025.
  • The last three reported values for Cash & Equivalents were $101.5 million (Q4 2025), $110.9 million (Q3 2025), and $53.7 million (Q2 2025) per Business Quant data.